Kamada (NASDAQ:KMDA) Stock Passes Below Two Hundred Day Moving Average – What’s Next?

Shares of Kamada Ltd. (NASDAQ:KMDA) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.02 and traded as low as $7.05. Kamada shares last traded at $7.26, with a volume of 65,733 shares.

Wall Street Analysts Forecast Growth

KMDA has been the subject of several research analyst reports. Stifel Nicolaus set a $11.00 target price on shares of Kamada in a research report on Wednesday, March 11th. Weiss Ratings cut shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday. Wall Street Zen downgraded Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Benchmark reissued a “buy” rating on shares of Kamada in a report on Thursday, March 12th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.00.

Kamada Price Performance

The stock’s fifty day simple moving average is $7.78 and its two-hundred day simple moving average is $8.02. The company has a market capitalization of $417.52 million, a price-to-earnings ratio of 20.74, a PEG ratio of 0.66 and a beta of 0.83.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). The business had revenue of $45.24 million for the quarter, compared to the consensus estimate of $46.72 million. Kamada had a net margin of 11.21% and a return on equity of 7.73%. On average, sell-side analysts predict that Kamada Ltd. will post 0.44 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Barclays PLC grew its stake in Kamada by 417.1% during the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after buying an additional 3,862 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Kamada in the fourth quarter valued at $66,000. XTX Topco Ltd acquired a new position in shares of Kamada during the fourth quarter valued at $103,000. SIH Partners LLLP acquired a new position in shares of Kamada during the fourth quarter valued at $134,000. Finally, Quadrature Capital Ltd boosted its holdings in shares of Kamada by 53.5% during the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 7,627 shares during the period. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.